AstraZeneca is launching a $1.5 billion savings plan to fund its drug pipeline. The U.K. drugmaker benefited from strong sales of cancer drugs that offset the effect of patent expirations and lifted the group’s top line. The company announced the initiative as it seeks to maintain momentum amid growing competition in the pharmaceutical sector.
Executives stated the cost-saving measures will not impact research and development spending, which remains a priority. The plan includes streamlining operations and optimizing manufacturing processes across global sites. AstraZeneca’s recent performance has been bolstered by its oncology portfolio, particularly drugs like Tagrisso and Imfinzi.
The savings are expected to be realized over the next three years. The move comes as the industry faces pressure to innovate while managing rising costs. AstraZeneca continues to invest in early-stage therapies and strategic partnerships to sustain long-term growth.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing